SCHEMBL735170

SCHEMBL735170

Cc1cccc2nc(CSc3ncnc4[nH]cnc34)n(CCc3ccccc3)c(=O)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CG P48736 9/20 0.51
CASR P41180 2/20 0.47
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 1/20 0.40
RXFP1 Q9HBX9 1/20 0.40
POLB P06746 1/20 0.40
RECQL P46063 1/20 0.40
PIK3CD O00329 4/20 0.39
PIK3CB P42338 1/20 0.39
TSHR P16473 1/20 0.39
PIK3R1 P27986 1/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 1/20 0.38
RGS12 O14924 1/20 0.38
USP2 O75604 1/20 0.38
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
MCOLN3 Q8TDD5 1/20 0.38
ADORA2B P29275 2/20 0.38
LMNA P02545 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL735492 0.90 PIK3CG (0.46) PIK3CGCASRHSD17B10ALDH1A1POLB
SCHEMBL6757118 0.89 PIK3CG (0.44) PIK3CGCASRHSD17B10ALDH1A1RXFP1
SCHEMBL7164778 0.86 PIK3CG (0.49) PIK3CGHSD17B10ALDH1A1RXFP1POLB
SCHEMBL735284 0.85 PIK3CG (0.51) PIK3CGHSD17B10ALDH1A1RXFP1POLB
SCHEMBL734677 0.84 PIK3CG (0.50) PIK3CGHSD17B10ALDH1A1RXFP1POLB
SCHEMBL6757116 0.83 PIK3CG (0.40) PIK3CGCASRHSD17B10ALDH1A1RXFP1
SCHEMBL734881 0.82 PIK3CG (0.68) PIK3CGPOLBRECQLPIK3CDPIK3CB
SCHEMBL24846340 0.82 POLB (0.54) PIK3CGCASRHSD17B10ALDH1A1RXFP1
SCHEMBL733352 0.81 PIK3CG (0.48) PIK3CGMAPT
SCHEMBL734521 0.81 PIK3CG (0.55) PIK3CGHSD17B10ALDH1A1RXFP1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140154772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA ICOS CORPORATION (US) 2014-06-05 US claimed
EP-1278748-B1 INHIBITORS OF HUMAN PHOSPHATIDYL-INOSITOL 3-KINASE DELTA ICOS CORP (US) 2011-03-23 EP claimed
EP-1885356-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2008-02-13 EP claimed
EP-1755609-A1 METHODS FOR TREATING AND/OR PREVENTING ABERRANT PROLIFERATION OF HEMATOPOIETIC CELLS ICOS CORPORATION (US) 2007-02-28 EP claimed
EP-1750715-A1 METHODS FOR TREATING MAST CELL DISORDERS ICOS CORPORATION (US) 2007-02-14 EP claimed
EP-1750714-A1 PHOSPHOINOSITIDE 3-KINASE DELTA SELECTIVE INHIBITORS FOR INHIBITING ANGIOGENESIS VANDERBILT UNIVERSITY (US) 2007-02-14 EP claimed
WO-2006089106-A2 PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2006-08-24 WO claimed
US-20060106038-A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells ICOS CORPORATION (US) 2006-05-18 US claimed
US-20060079538-A1 Methods for inhibiting angiogenesis VANDERBILT UNIVERSITY 2006-04-13 US claimed
WO-2005120511-A1 METHODS FOR TREATING MAST CELL DISORDERS ICOS CORPORATION (US) 2005-12-22 WO claimed
US-6949535-B2 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one ICOS CORPORATION (US) 2005-09-27 US claimed
WO-2005067901-A2 METHODS FOR TREATING AND PREVENTING HYPERTENSION AND HYPERTENSION-RELATED DISORDERS MICHIGAN STATE UNIVERSITY (US) 2005-07-28 WO claimed
US-20050054614-A1 Methods of inhibiting leukocyte accumulation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-03-10 US claimed
US-20050043239-A1 Methods of inhibiting immune responses stimulated by an endogenous factor ICOS CORPORATION 2005-02-24 US claimed
WO-2005016349-A1 METHODS OF INHIBITING LEUKOCYTE ACCUMULATION ICOS CORPORATION (US) 2005-02-24 WO claimed
WO-2005016348-A1 METHOD OF INHIBITING IMMUNE RESPONSES STIMULATED BY AN ENDOGENOUS FACTOR ICOS CORPORATION (US) 2005-02-24 WO claimed
US-20040266780-A1 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one ICOS CORPORATION 2004-12-30 US claimed
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta ICOS CORPORATION 2003-10-16 US claimed
US-6518277-B1 Disrupting leukocyte function ICOS CORPORATION 2003-02-11 US claimed
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives ICOS CORPORATION, A DELAWARE CORPORATION 2002-10-31 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054614-A1 Methods of inhibiting leukocyte accumulation PI4KB, PIK3CD, PIK3CA PIK3CG 7/4885CASR 3654/4885HSD17B10 2437/4885
US-20140154772-A1 INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885CASR 3943/4885HSD17B10 2243/4885
US-20020161014-A1 Purinyl substituted quinazoline-4-one derivatives PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885CASR 4553/4885HSD17B10 4340/4885
US-20060079538-A1 Methods for inhibiting angiogenesis FLT4, KDR, PDGFRB PIK3CG 13/4885CASR 3452/4885HSD17B10 1042/4885
US-20040266780-A1 for example, 2-(6-aminopurin-9-ylmethyl)-3-(2-chlorophenyl)-6,7-dimethoxy-3H-quinazolin-4-one PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885CASR 4639/4885HSD17B10 2966/4885
US-20050043239-A1 Methods of inhibiting immune responses stimulated by an endogenous factor PI4KB, PI4KA, PIK3CD PIK3CG 10/4885CASR 1372/4885HSD17B10 3629/4885
US-20060106038-A1 Methods for treating and/or preventing aberrant proliferation of hematopoietic cells MCL1, NFATC1, MKI67 PIK3CG 57/4885CASR 2656/4885HSD17B10 2509/4885
US-20030195211-A1 Inhibitors of human phosphatidylinositol 3-kinase delta PIK3CD, PIK3CA, PIK3CG PIK3CG 3/4885CASR 4374/4885HSD17B10 2106/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.